Q3 EPS Estimate for Nektar Therapeutics Raised by Analyst

Nektar Therapeutics (NASDAQ:NKTR) – Equities researchers at Zacks Research lifted their Q3 2026 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Thursday, September 3rd. Zacks Research analyst Team now expects that the biopharmaceutical company will earn ($2.45) per share for the quarter, up from their prior forecast of ($3.05). The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($8.28) per share. Zacks Research also issued estimates for Nektar Therapeutics’ Q4 2026 earnings at ($3.07) EPS, FY2026 earnings at ($8.58) EPS, Q1 2027 earnings at ($3.17) EPS, Q2 2027 earnings at ($3.06) EPS, Q3 2027 earnings at ($4.28) EPS, Q4 2027 earnings at ($5.65) EPS, FY2027 earnings at ($16.15) EPS, Q1 2028 earnings at ($4.28) EPS, Q2 2028 earnings at ($3.82) EPS and FY2028 earnings at ($17.77) EPS.

Other research analysts also recently issued reports about the stock. TD Cowen raised shares of Nektar Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Canaccord Genuity Group initiated coverage on shares of Nektar Therapeutics in a research note on Wednesday, July 22nd. They set a “buy” rating and a $153.00 target price on the stock. JPMorgan Chase & Co. assumed coverage on shares of Nektar Therapeutics in a research note on Friday, August 21st. They set a “neutral” rating and a $65.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nektar Therapeutics in a research report on Friday, August 28th. Finally, Wall Street Zen raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Nektar Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $141.50.

Nektar Therapeutics Stock Up 1.7%

Shares of NKTR stock opened at $75.44 on Monday. The stock has a fifty day moving average of $72.10 and a 200 day moving average of $72.11. Nektar Therapeutics has a 52 week low of $33.40 and a 52 week high of $109.00. The firm has a market capitalization of $2.58 billion, a price-to-earnings ratio of -11.26 and a beta of 1.14.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.97) by $0.74. The firm had revenue of $10.13 million for the quarter, compared to analyst estimates of $10.43 million. Nektar Therapeutics had a negative return on equity of 37.87% and a negative net margin of 287.84%.

Institutional Investors Weigh In On Nektar Therapeutics

Hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its stake in shares of Nektar Therapeutics by 93.8% during the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 210 shares in the last quarter. KBC Group NV purchased a new stake in shares of Nektar Therapeutics in the 1st quarter worth approximately $52,000. Headlands Technologies LLC purchased a new stake in shares of Nektar Therapeutics in the 2nd quarter worth approximately $65,000. State of Wyoming bought a new position in Nektar Therapeutics during the 1st quarter valued at approximately $67,000. Finally, Integrated Wealth Concepts LLC bought a new position in Nektar Therapeutics during the 1st quarter valued at approximately $68,000. Institutional investors own 75.88% of the company’s stock.

Insider Buying and Selling at Nektar Therapeutics

In other news, insider Jonathan Zalevsky sold 5,681 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $70.00, for a total transaction of $397,670.00. Following the sale, the insider owned 9,756 shares in the company, valued at approximately $682,920. The trade was a 36.80% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Howard Robin sold 10,000 shares of the company’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $60.32, for a total transaction of $603,200.00. Following the completion of the sale, the chief executive officer directly owned 65,045 shares in the company, valued at $3,923,514.40. This represents a 13.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 21,823 shares of company stock valued at $1,380,558 in the last three months. Insiders own 2.50% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.